Microencapsulated Genetically Engineered Lactobacillus plantarum 80 (pCBH1) for Bile Acid Deconjugation and Its Implication in Lowering Cholesterol.
Microencapsulated Genetically Engineered Lactobacillus plantarum 80 (pCBH1) for Bile Acid Deconjugation and Its Implication in Lowering Cholesterol.
复制标题
DOI：
10.1155/s1110724304307011
复制
发表时间：
2004
影响因子：
--
通讯作者：
Prakash S
中科院分区：
文献类型：
--
作者：
Jones ML;Chen H;Ouyang W;Metz T;Prakash S
已知胆固醇是冠心病（CHD）的主要危险因素。目前针对血胆固醇升高的治疗方法包括饮食管理、定期锻炼以及使用贝特类药物、胆汁酸螯合剂和他汀类药物的药物治疗。然而，这种疗法通常是次优的，并且具有严重副作用的风险。本研究表明，微囊化植物乳杆菌80（pCBH 1）细胞能够有效地分解和去除胆汁酸，并为其用于降低血清胆固醇奠定了基础。结果表明，微囊化LP 80（pCBH 1）能有效地降解结合胆汁酸甘氨脱氧胆酸（GDCA）和牛磺脱氧胆酸（TDCA），其胆汁盐水解酶（BSH）活力分别为0.19和0.08 μmol DCA/mg CDW/h。本文还总结了胆汁酸和胆固醇之间的生理相互关系，并预测了降低胆固醇所需的微囊化植物乳杆菌80（pCBH 1）细胞的口服剂量。
Cholesterol is known to be a major risk factor for coronary heart disease (CHD). Current treatments for elevated blood cholesterol include dietary management, regular exercise, and drug therapy with fibrates, bile acid sequestrants, and statins. Such therapies, however, are often suboptimal and carry a risk for serious side effects. This study shows that microencapsulated Lactobacillus plantarum 80 (pCBH1) cells can efficiently break down and remove bile acids, and establishes a basis for their use in lowering blood serum cholesterol. Results show that microencapsulated LP80 (pCBH1) is able to effectively break down the conjugated bile acids glycodeoxycholic acid (GDCA) and taurodeoxycholic acid (TDCA) with bile salt hydrolase (BSH) activities of 0.19 and 0.08 μmol DCA/mg CDW/h respectively. This article also summarizes the physiological interrelationship between bile acids and cholesterol and predicts the oral doses of microencapsulated Lactobacillus plantarum 80 (pCBH1) cells required for lowering cholesterol.